Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on MASI: Masimo CorpShs NewsMORE ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Masimo originally requested $1.85 billion in damages, along with reasonable royalties, lost profits, and a penalty for willful trade secret appropriation. With the bench trial, Masimo is no longer ...

The jury voted 6 to 1 in favor of Apple on these claims. Furthermore, the judge ruled against Masimo's claims regarding Apple's hiring practices, noting that employees can move between companies.

Full-Year 2024 Non-GAAP EPS Guidance: $3.95 to $4.10. Unrecognized Contract Revenues: $1.65 billion as of the end of Q3. Masimo Corp (NASDAQ:MASI) reported healthcare revenues of $343 million for ...

Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents. The jury, in Delaware, agreed with Apple that Masimo's W1 and ...

Return on Equity (ROE): Masimo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.17%, the company may face hurdles in generating ...